Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Imports: President Bush Says Decision Could Come In December

This article was originally published in The Pink Sheet Daily

Executive Summary

Bush suggests during presidential debate that he is waiting for completion of drug importation task force’s report, due in December, before making a decision on whether to allow imports. The President says there is a possibility “you’ll hear me say, ‘I think there’s a safe way to do it.’”

You may also be interested in...



Rx Import Report: Task Force May Miss Dec. 8 Deadline

CMS Administrator McClellan says the drug import task force, of which he is a member, will publish its report “as close to the deadline as possible.” The Dec. 8 deadline for delivering the report to Congress is mandated under the Medicare Modernization Act.

Rx Import Report: Task Force May Miss Dec. 8 Deadline

CMS Administrator McClellan says the drug import task force, of which he is a member, will publish its report “as close to the deadline as possible.” The Dec. 8 deadline for delivering the report to Congress is mandated under the Medicare Modernization Act.

Bush Reelection Is "Very Good" For Drug Manufacturers, GSK Says

President Bush's reelection is good for the pharmaceutical industry because of his position on prescription drug importation, GlaxoSmithKline VP-Federal Government Relations Sally Walsh said Nov. 17

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057800

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel